I am a
Home I AM A Search Login

Papers of the Week

2022 Apr 08

Curr Med Res Opin

Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.


Pozo-Rosich P, Detke HC, Wang S, Doležil D, Li LQ, Aurora SK, Reuter U
Curr Med Res Opin. 2022 Apr 08:1-34.
PMID: 35392739.


Galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, was found to be safe and efficacious for the preventive treatment of chronic migraine based on the randomized, placebo-controlled double-blind period of the REGAIN study (Clinicaltrials.gov identifier: NCT02614261). Long-term safety and efficacy were assessed in an open-label extension.